| Dr Gerardo Antonio Vitiello, MD | |
|
301 E Main St, Bay Shore, NY 11706-8408 | |
| (631) 968-3000 | |
| Not Available |
| Full Name | Dr Gerardo Antonio Vitiello |
|---|---|
| Gender | Male |
| Speciality | Surgery - Surgical Oncology |
| Location | 301 E Main St, Bay Shore, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194135848 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086X0206X | Surgery - Surgical Oncology | 284100 (New York) | Primary |
| Entity Name | North Shore - Lij Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053688572 PECOS PAC ID: 3375701568 Enrollment ID: O20120220000262 |
News Archive
IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration ("FDA") for its next -generation fully automated Enzyme-linked Immunosorbent Assay ("ELISA") system for autoimmune and infectious disease testing, named the Mago®4S.
Mendor, the Finnish diabetes technology company, continues its rapid growth and is excited to announce yet another international partnership - now opening the United Kingdom for its innovative products. Mendor has just signed a distribution agreement with a leading pharmaceutical company in the Diabetes field Merck Serono, covering the United Kingdom diabetes market.
People with a family history of certain diseases, including heart disease and diabetes, often underestimate their risk for developing them, even after completing a risk assessment and receiving personalized prevention messages, finds a new study in the American Journal of Preventive Medicine.
Propanc Health Group Corporation, an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, is pleased to announce it has executed an equity purchase agreement (the "EPA") with Southridge Partners II, L.P., an institutional investor, in the amount of $5 million, which will create significant growth capital for Propanc, enabling the execution of its business plan, on favorable terms.
Miglustat is a drug currently under phase 2 clinical trials on patients suffering from cystic fibrosis (1). Its potential for treating the disease was discovered in 2006 thanks to the work of Frédéric Becq's team at the Institute of Cell Physiology and Biology (CNRS/Université de Poitiers), funded by the associations Vaincre la Mucoviscidose, MucoVie66, La Pierre Le Bigaut and ABCF2.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gerardo Antonio Vitiello, MD 301 E Main St, Bay Shore, NY 11706-8408 Ph: () - | Dr Gerardo Antonio Vitiello, MD 301 E Main St, Bay Shore, NY 11706-8408 Ph: (631) 968-3000 |
News Archive
IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration ("FDA") for its next -generation fully automated Enzyme-linked Immunosorbent Assay ("ELISA") system for autoimmune and infectious disease testing, named the Mago®4S.
Mendor, the Finnish diabetes technology company, continues its rapid growth and is excited to announce yet another international partnership - now opening the United Kingdom for its innovative products. Mendor has just signed a distribution agreement with a leading pharmaceutical company in the Diabetes field Merck Serono, covering the United Kingdom diabetes market.
People with a family history of certain diseases, including heart disease and diabetes, often underestimate their risk for developing them, even after completing a risk assessment and receiving personalized prevention messages, finds a new study in the American Journal of Preventive Medicine.
Propanc Health Group Corporation, an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, is pleased to announce it has executed an equity purchase agreement (the "EPA") with Southridge Partners II, L.P., an institutional investor, in the amount of $5 million, which will create significant growth capital for Propanc, enabling the execution of its business plan, on favorable terms.
Miglustat is a drug currently under phase 2 clinical trials on patients suffering from cystic fibrosis (1). Its potential for treating the disease was discovered in 2006 thanks to the work of Frédéric Becq's team at the Institute of Cell Physiology and Biology (CNRS/Université de Poitiers), funded by the associations Vaincre la Mucoviscidose, MucoVie66, La Pierre Le Bigaut and ABCF2.
› Verified 6 days ago
Dr. Bradley David Cohen, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 15 Park Ave, Bay Shore, NY 11706 Phone: 631-581-4400 Fax: 631-277-3750 | |
Dr. Manal Hegazy, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 15 Park Ave, Bay Shore, NY 11706 Phone: 631-581-4400 Fax: 631-277-3750 | |
Alexandra Capece, DO Surgery Medicare: Medicare Enrolled Practice Location: 440 E Main St Ste A, Bay Shore, NY 11706 Phone: 520-414-8000 | |
Dr. Charles A La Rosa, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 15 Park Ave, Bay Shore, NY 11706 Phone: 631-581-4400 Fax: 631-277-3750 | |
Dr. Kelechi Akuma, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 250 E Main St, Bay Shore, NY 11706 Phone: 631-470-1460 | |
Dr. Marinel Ardeljan, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 10 Brentwood Rd, Bay Shore, NY 11706 Phone: 631-665-8200 Fax: 631-665-8914 |